trending Market Intelligence /marketintelligence/en/news-insights/trending/ijj0hsqrizqbimpgdmjtxw2 content esgSubNav
In This List

Abeona drug gets US FDA rare pediatric disease designation

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Abeona drug gets US FDA rare pediatric disease designation

Abeona Therapeutics Inc. said its investigative gene therapy ABO-202 received the U.S. Food and Drug Administration's rare pediatric disease designation.

The Dallas-based biopharmaceutical company is studying the medicine for treating the infantile Batten disease, which affects the nervous system in newborns.

In February, the investigational medicine received the U.S. FDA's orphan drug designation.